Brenig Therapeutics, Inc.
brenigther.com
Actively hiring
Neurology & CNS Therapeutics
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$65M
1 round on record
Latest round
$65M
Series A · Jul 2024 · 2 yr ago
Backers
2
BioGeneration Ventures, OrbiMed
The money's age
Long since its last round
26 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 30, 2025
New executive Brenig Therapeutics Names Megan McGill as Chief Executive Officer · brenigther.com
Jul 10, 2025
New executive BRENIG THERAPEUTICS ANNOUNCES APPOINTMENTS OF DAVID L. LUCCHINO AS CEO AND TIEN DAM, M.D., AS CHIEF MEDICAL OFFICER, EXPANDS PIPELINE · abc27.com
Jul 22, 2024
Raised a round Series A $65M
Dec 4, 2023
Launched Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson's Disease Con… · brenigther.com
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Jul 2024 | $65M | — | medindia.net |
Backed byfrom the funds' portfolios and accelerator catalogs
OrbiMed Similar startupsby what they do, their industry and backers
A biotech company dedicated to developing transformative medicines for people with neurodegenerative diseases using cutting-edge science…
Our Mission. Deliver medicines that transform the lives of patients with neurodegenerative diseases.
We are on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases.
Restoring energy. Next-generation disease-modifying medicines for ALS and Parkinson's.
Accelerating the development of better drugs for better targets in a quest to alter the trajectory of neurodegenerative disease.
Biomia rationally engineers nature-inspired novel small molecule therapeutics to treat CNS disorders.
News
Brenig Therapeutics to Present AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor at Keystone Symposia Neuroinflammation in Health and Disease
Boston, MA, and San Diego, CA, June 22, 2026 - Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing differentiated therapies for neurodegenerative and neuroinflammatory diseases, today announced that Alexei Pushechnikov, Ph
Read more
Report
Brenig Therapeutics to Present AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor at Keystone Symposia Neuroinflammation in Health and Disease
Read more
Report
Brenig Therapeutics to Present Hybrid AI Drug Discovery Platform at Keystone Symposia Computational Advances in Drug Discovery
Boston, MA, and San Diego, CA, April 30th, 2026 - Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company advancing best-in-class therapies for neurodegenerative, neuroinflammatory, and cardiometabolic diseases, today announced that Alex
Read more
Report
Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Boston, MA, April 16th, 2026 - Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing brain-penetrant small molecule therapies for neurodegenerative diseases, today announced that data from its ongoing Phase 1 healthy volunte
Read more
Report
Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program
Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurologic diseases, today announced that Tien Dam, MD, Chief Medical Officer, will present interim data from the Company
Read more
Report
Pro access
Upgrade to see all 17 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Financials
Total raised
$65M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2024 | $65M | Details |